Washington DC, June 10: A new set of expert consensus-based recommendations lays out how best is to study possible neurodevelopmental impacts of pubertal suppression treatment in transgender youth.

Developed by a consensus panel of 24 international scientists, the recommendations were published in the journal Transgender Health. Also Read | Anand Sagar's Ramayan: Debina Bonnerjee Reveals Why the Initial Days of Shooting Were Very Taxing For Her and Gurmeet Choudhary.

While early evidence suggests suppressing puberty has positive effects on the mental health of transgender adolescents, little is known about how this standard of care treatment affects an adolescent's brain development. Also Read | Twitter, Square to Celebrate Juneteenth Which Commemorates Ending of Slavery in US, Announce Company Holiday on June 19.

"We don't know how stopping puberty for a year or more affects a transgender adolescent's neurocognitive development. Clearly, pubertal suppression is important for many transgender youth, but at this time, we can't speak to a family's questions about how this medical treatment might affect brain development," said Diane Chen, Ph.D., co-lead author of the study and Behavioral Health Director for the Potocsnak Family Division of Adolescent and Young Adult Medicine at the Ann and Robert H Lurie Children's Hospital of Chicago.

"We need high-quality research to understand the impacts of this treatment - impacts which may be positive in some ways and potentially negative in others. This information about benefits and risks will help young people make informed decisions and assist providers in knowing how best to provide this treatment for optimal outcomes," said John Strang, Psychology Department, co-lead author and director of Research for the Children's National Hospital Gender Development Program.

Transgender youth, who are on the verge of developing sex-based characteristics that don't align with their gender identity, often work with their care providers to suppress pubertal development via gonadotropin-releasing hormone agonists (GnRHa). This medication approach suspends the production of gonadal (sex) hormones for as long as GnRHa is administered, which is often 1-2 years.

Employing a Delphi consensus method that included 24 international experts from the fields of adolescent neurodevelopment, gender development, neuroendocrinology and measurement science, the authors identified three primary domains of neurodevelopment that should be measured in these studies: mental health, executive function/cognitive control and social awareness/functioning.

In addition, the authors identified 44 study design elements, that all experts agreed were crucial components, out of the original 160 identified at study start. The consensus elements include measuring neurodevelopment domains repeatedly over time, before and during treatment.

Other elements include identification of an individual's stage of puberty prior to treatment, application of analytical approaches that account for the heterogeneity, or broad range of differences that exist between transgender individuals.

Incorporating comparisons between multiple groups, including untreated transgender youth at the same pubertal stage, cisgender youth at the same pubertal stage, and an independent sample from available largescale youth databases are also the elements of the consensus.

"This is a critical topic for transgender youth and their families. It is also a difficult topic to study because we would never randomly assign transgender youth to treatment and no treatment groups - that would be harmful and unethical," said Dr Strang.

"Instead, we gathered the world's experts in relevant fields to work together and design the best possible research approaches to study the effects of this treatment without relying on a randomized treatment design," Dr Chen added.

(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)